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Abstract
Background: Dupuytren’s disease is a fibroproliferative disorder of the palmar fascia. The treatment used to date
has mostly been surgery, but there is a high recurrence rate. Transforming growth factor b (TGF-b) has been
implicated as a key stimulator of myofibroblast activity and fascial contraction in Dupuytren’s disease.
Results: We studied Dupuytren’s fibroblasts in tissues ex vivo and in cells cultured in vitro and found increased
TGF-b expression compared to control fibroblasts. This correlated not only with elevated expression and activation
of downstream Smad effectors but also with overactive extracellular signal-regulated kinase 1/2 (ERK1/2)/mitogen-
activated protein (MAP) kinase signalling. Treatment with the TGF-b type I receptor kinase inhibitor SB-431542 and
bone morphogenetic protein 6 (BMP6) led to inhibition of elevated Smad and ERK1/2/MAP kinase signalling as
well as to inhibition of the increased contractility of Dupuytren’s fibroblasts. BMP6 attenuated TGF-b expression in
Dupuytren’s fibroblasts, but not in control fibroblasts. Platelet-derived growth factor (PDGF) expression was strongly
promoted by TGF-b in Dupuytren’s fibroblasts and was curbed by SB-431542 or BMP6 treatment. High basal
expression of phosphorylated ERK1/2 MAP kinase and fibroproliferative markers was attenuated in Dupuytren’s
fibroblasts by a selective PDGF receptor kinase inhibitor. Cotreatment of Dupuytren’s fibroblasts with SB-431542
and the mitogen-activated protein kinase kinase 1 inhibitor PD98059 was sufficient to abrogate proliferation and
contraction of Dupuytren’s fibroblasts.
Conclusions: Both TGF-b and ERK1/2 MAP kinase pathways cooperated in mediating the enhanced proliferation
and high spontaneous contraction of Dupuytren’s fibroblasts. Our data indicate that both signalling pathways are
prime targets for the development of nonsurgical intervention strategies to treat Dupuytren’s disease.
Background
Dupuytren’s disease (DD) is a common fibroproliferative
condition that only affects the hand. The characteristic
feature is a progressive contracture of the palm and fin-
gers. Patients commonly first display a nodule in the
palm or on the volar (palmar) aspect of the fingers
caused by a thickened layer of tissue (palmar fascia)
between the skin and the tendons of the hand and fin-
gers. The nodule is a key diagnostic feature and
represents the early proliferative stage of the disease.
The nodules contain mostly myofibroblasts [1,2]. As the
disease progresses, the nodules may disappear and give
w a yt ot h ef o r m a t i o no fc o r d s .T h e s ec o r d sr e p r e s e n t
characteristics of fibrosis within the involutional and
residual stages of the disease and comprise mostly fibro-
blasts and extracellular matrix (ECM).
Treatment of DD consists largely of surgical excision
of the contracted tissue. Because of high recurrence
rates following surgery, investigations are underway to
determine the underlying causes of DD to optimise
treatment strategies [1,2]. The myofibroblast, a specia-
lised fibroblast phenotype that expresses a-smooth mus-
cle actin (a-SMA), provides the cell with contractile
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implicated in Dupuytren’s contracture; transforming
growth factor b (TGF-b) in particular has been pro-
posed to play a prominent role [6].
TGF-b is a member of a protein family that also includes
activins, nodal and bone morphogenetic proteins (BMPs).
TGF-b protein family members signal through type I and
type II serine/threonine kinase receptors [7]. Type I recep-
tors are also called ‘activin receptor-like kinases’ (ALKs).
ALK4, ALK5 and ALK7 are type I receptors of activin,
TGF-b and nodal protein kinases, respectively. SB-431542
is a selective inhibitor of ALK4, ALK5 and ALK7 kinase
activity [8]. Signalling from activated type I receptors is
mainly transduced into the cytoplasm through phosphory-
lation of receptor-regulated Smads (R-Smads). Activated
ALK4, ALK5 and ALK7 induce phosphorylation of Smad2
and Smad3. BMPs mediate the activation of Smad1,
Smad5 and Smad8. Activated R-Smads form heteromeric
complexes with Smad4 that accumulate in the nucleus,
where they regulate gene expression, including plasmino-
gen activator inhibitor 1 (PAI-1; also known as SERPINE1,
aT G F - b/ALK5 target gene) and the inhibitor of DNA
binding 1 gene (a BMP target gene) [7]. TGF-b can also
activate non-Smad pathways, including the extracellular
signal-regulated kinase (ERK) mitogen-activated protein
(MAP) kinase signalling pathway [9,10]. TGF-b is a potent
modulator of fibroblast and myofibroblast proliferation
and differentiation [3,11-13]. Previous studies of DD tissue
found increased protein synthesis and expression of all
three TGF-b isoforms and their receptors [14-18]. In vitro
contraction assays revealed that TGF-b stimulation gener-
ates or increases contractile force in Dupuytren-derived
cells [19-23]. In addition, TGF-b stimulation leads to upre-
gulation of key ECM components, such as fibronectin and
type I collagen (COL1), and this effect either may be direct
or may occur indirectly via enhanced expression of matri-
cellular protein connective tissue growth factor (CTGF/
CCN2) [24,25]. TGF-b stimulation can also induce the
expression of growth factors, such as platelet-derived
growth factor (PDGF) [26].
It is not known whether BMPs play a role in DD.
Compared to normal fascia-derived cells, Dupuytren-
derived cells do not express BMP4 and exhibit
decreased BMP6 and BMP8 expression [27]. A previous
study found that there is decreased BMP receptor
expression and, apparently, reduced BMP responsiveness
in DD tissue, which has constrained research into BMPs
as potential antagonists of TGF-b-induced fibrosis in
DD as described in kidney and liver fibrosis [28].
In this study, we investigated the aberrant activation
of the TGF-b/Smad and PDGF/ERK1/2/MAP kinase
pathways in DD tissue specimens and cell culture. Using
BMP6 and selective chemical inhibitors of the TGF-b
receptors, the PDGF receptors and the MAP kinase
pathway, we attempted to counteract the fibrogenic
characteristics of DD. Our insights may contribute to
the development of new therapeutic strategies for sus-
tained, nonsurgical treatment of DD.
Methods
Clinical specimens
DD tissue specimens were obtained from four adult
patients undergoing fasciectomy for DD. Patients who
underwent carpal tunnel release and showed no evi-
dence of DD contributed the control tissue from normal
palmar fascia (n = 3) or carpal ligament (n =1 ) .A l lD D
tissues used were from primary releases. The tissue was
separated macroscopically in nodules and cords. Only
nodules were used in this study. For details on how
samples were prepared, see the Additional files.
Clinical sample preparation
After excision, the nodule was divided in three portions.
One portion was placed in 10% formalin and further
processed for immunohistochemistry. The second was
immediately placed into liquid nitrogen for protein
extraction. The third portion was used for primary cell
culture. All of the patients underwent excision indepen-
dently of this study and had not undergone previous
surgery on their hands. Oral consent for removal of the
tissue and storage in the tissue bank for research pur-
poses was obtained from the patients. Individual consent
for this specific project was waived by the local ethics
committee because the research was performed on
‘waste’ material, which was stored in a coded fashion.
Reagents
Recombinant human TGF-b3 (OSI Pharmaceuticals Inc.,
Melville, NY, USA) and recombinant human BMP6 (Crea-
tive BioMolecules, Hopkinton MA, USA) were generously
provided by K Iwata and K Sampath, respectively. SB-
431542 compound, which targets ALK4, ALK5 and ALK7,
was purchased from Tocris Bioscience, Ellisville, Missouri,
USA. The PD98059 compound, which targets mitogen-
activated protein kinase kinase 1 (MEK1), was purchased
from Cell Signaling Technology (Danvers, MA, USA). The
vascular endothelial growth factor (VEGF) receptor inhibi-
tor PTK787/ZK222584, the epidermal growth factor
(EGF) receptor inhibitor PKI166 and the PDGF receptor
inhibitor STI571 (also known as imatinib mesylate) were
kindly provided by Novartis, Amsterdam, The Nether-
lands. The protein kinase C activator 12-O-tetradecanoyl-
phorbol-13-acetate (TPA) was obtained from Sigma
(Sigma Chemical Co., St. Louis, MO, USA).
Cell culture
To obtain primary cells, tissues were minced under sterile
conditions into pieces that measured approximately 1 × 1
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3. Ten to twenty pieces were placed as explants
into the wells of six-well plates and stored in 37°C incuba-
tors in 5% CO2. Primary cells from passages 3 through 6
were used for the experiments. All of the cells were sub-
cultured in DMEM containing 4.5 g/L glucose (Gibco,
Breda, The Netherlands) supplemented with 10% foetal
bovine serum (FBS) (Integro, Zaandam, The Netherlands),
100 IU/mL penicillin and 100 IU/mL streptomycin (Invi-
trogen, Breda, The Netherlands).
RNA isolation and quantitative real-time PCR
Total RNA was extracted by using the RNeasy Kit (Qia-
gen, Venlo, The Netherlands) according to the manufac-
turer’s instructions. Reverse transcriptase PCR was
performed using the RevertAid H Minus First Strand
cDNA Synthesis Kit (Fermentas, St. Leon-Rot, Germany)
according to the manufacturer’s instructions. All of the
samples were plated in duplicate, and TaqMan PCR
reactions were performed using the StepOnePlus Real-
Time PCR System (Applied Biosystems, Carlsbad, Cali-
fornia, USA). Lack of DNA contamination was verified
and gene expression levels were determined using the
comparative ΔCt method with glyceraldehyde 3-phos-
phate dehydrogenase (GAPDH) as the reference.
Quantitative PCR primers
Human TGF-b1 through TGF-b3, a-SMA, PAI-1, c-myc,
COl1A2, fibronectin, Smad1 through Smad3, CTGF,
PDGF-A, PDGF-B and GAPDH gene expression was
analysed using the following forward and reverse pri-
mers: TGF-b1,5 ’-CTCTCCGACCTGCCACAGA-3’ and
5’-AACCTAGATGGGCGCGATCT-3’; TGF-b2,5 ’-CCG
CCCACTTTCTACAGACCC-3’ and 5’-GCGCTGGG
TGGGAGATGTTAA-3’; TGF-b3,5 ’-CTGGCCCT
GCTGAACTTTG-3’ and 5’-AAGGTGGTGCAAGTG-
GACAGA-3’; a-SMA,5 ’-CACCTTCCAGCAGATGTG-
GAT-3’ and 5’-AAGCATTTGCGGTGGACAAT-3’;
PAI-1,5 ’-TCTTTGGTGAAGGGTCTGCT-3’ and 5’-CT
GGGTTTCTCCTCCTGT TG-3’; c-myc,5 ’-CGTCTC
CACACATCAGCACAA-3’ and 5’-CACTGTCCAA
CTTGACCCTCTTG-3’; COl1A2,5 ’-GATGTTGAAC
TTGTTGCTGAGG-3’ and 5’-TCTTTCCCCATTC
ATTTGTCTT-3’; fibronectin,5 ’-GAGGCCACCATCA
CTGGTT-3’ and 5’-AGTGCGATGACATAGA
TGGTGTA-3’; Smad1,5 ’-TGAACCATGGATTTGAGA
CAGT-3’ and 5’-CTGGCGGTGGTATTCTGC-3’;
Smad2,5 ’-CGAAAAGGATTGCCACATGTT-3’ and 5’-
TTGAGTTCATGATGACTGTGAAGATC-3’; Smad3,
5’-CGGTCAACCAGGGCTTTG-3’ and 5’-CAGCCTTT
GACGAAGCTCATG-3’; CTGF,5 ’-TTGCGAAGCT
GACCTGGAAGAGAA-3’ and 5’-AGCTCGGTATG
TCTTCATGCTGGT-3’; PDGF-A,5 ’-CCTCACAT
CCGTGTCCTCTT-3’ and 5’-ACACGAGCAGTGT-
CAAGTGC-3’; PDGF-B,5 ’-TGCTGTTGAGGTGG
CTGTAG-3’ and 5’-GAAAATGCAGGGTGGAGGTA-
3’; TGF-a,5 ’-TAACCACGAGACCCTCAACC-3’ and 5’-
CCCAAGCCTTAGCTGTCTTG-3’;a n dGAPDH,5 ’-AT
CACTGCCACCCAGAAGAC-3’ and 5’-ATGAGGTCC
ACCACCCTGTT-3’.
MTS-based proliferation assay
Cells were seeded into 96-well plates at 7 × 10
3 cells/
well and treated the next day with the indicated inhibi-
tors or DMSO as a control. Increases in the number of
viable cells after culture were measured daily for 4 days
using an 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxy-
methoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium
(MTS)-based proliferation assay according to the manu-
facturer’s instructions (CellTiter 96 AQueous One Solu-
tion Cell Proliferation Assay System; Promega, Leiden,
The Netherlands) and using the measured absorbance at
490 nm on day 0 as the reference.
Tissue lysate preparation and Western blot analysis
For tissue lysates, biopsies were frozen in liquid nitrogen
and pulverised using a mortar. Thereafter, the triturated
tissues were incubated in ice-cold lysis buffer (150
mmol NaCl, 20 mmol Tris·HCl, pH 7.5, 1% Nonidet P-
40, 5 mmol sodium ethylenediaminetetraacetic acid
(EDTA) and one Complete Protease Inhibitor Cocktail
Tablet (Roche, Woerden, The Netherlands) per 50 mL
of solution) for 30 minutes. Prior to centrifugation at 4°
Cf o r1 5m i n u t e sa t1 4×1 0
3 rpm, the samples under-
went extensive vortexing and sonification. The total pro-
tein content of the supernatant was determined using
the DC Protein Assay (Bio-Rad Laboratories, Veenen-
daal, The Netherlands)). Equal amounts of total protein
(100 μg/μL) were loaded onto a 10% gel, followed by
SDS-PAGE and Western blot analysis. For cell-based
assays, cells were plated onto six-well plates at a density
of 4 × 10
5 cells/well, stimulated with the indicated
reagents and directly lysed in sample buffer (250 mmol
Tris·HCl, pH 6.8, 8% SDS, 40% glycerol, 5% b-mercap-
toethanol, and bromophenol blue) after 18 hours. Anti-
bodies specifically targeting Smad1 (Zymed, San
Francisco, CA, USA), Smad2/3 (BD Transduction
Laboratories, Breda, The Netherlands), phosphorylated
ERK1/2 (P-ERK1/2; Cell Signaling Technology), PAI-1
(Santa Cruz Biotechnology, Santa Cruz, CA, USA),
Col1a 2 (Col1A2; SouthernBiotech, Birmingham, Ala-
bama, USA), a-SMA (Sigma Chemical Co.), fibronectin/
ED-A (Abcam, Cambridge, MA, USA) and c-myc (Santa
Cruz Biotechnology) were purchased. Antibodies target-
ing phosphorylated Smad1 and Smad2 (P-Smad1 and P-
Smad2, respectively) were described previously [29]. P-
Smad3 was obtained from E Leof (Mayo Clinic, Roche-
s t e r ,M N ,U S A ) ,a n dP - E R K 1 / 2a n t i b o d i e sw e r eag i f t
from WH Moolenaar (Netherlands Cancer Institute,
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firmed using an anti-b- a c t i na n t i b o d y( S i g m aC h e m i c a l
Co.). Quantitative Western blot analysis was performed
using secondary goat anti-rabbit IRDye 680 and goat
anti-mouse IRDye 800 CW with the Odyssey Scanner
(LI-COR Biosciences, Lincoln, Nebraska USA) according
to the manufacturer’s instructions.
Immunofluorescence
For immunofluorescence staining, cells were grown on
coverslips overnight. Cells were fixed with ice-cold
methanol for 30 minutes, washed twice with PBS,
quenched with 20 mmol NH4Cl, and permeabilised with
0.1% Triton X-100 the following day. Cells were then
incubated in blocking solution (PBS containing 3.0%
BSA) for 45 minutes followed by incubation for 1 hour
with anti-a-SMA antibody (Sigma Chemical Co.) diluted
1:100 in blocking solution. After washing, the labelled
secondary antibody Alexa Fluor 488 goat anti-mouse
immunoglobulin G (IgG) (Invitrogen) was used. Nuclei
were stained using Hoechst 33258 (Invitrogen) accord-
ing to the manufacturer’s instructions. Specimens were
visualised by using an Olympus IX51 inverted micro-
scope at ×100 magnification using the cell
F Soft Imaging
System (Olympus, Zoeterwoude, The Netherlands).
Immunocytochemistry
Cells were cultured overnight on coverslips. The next
day fixation in acetone followed by staining for a-SMA
(a-SMA/1, M851, 1A4 clone; Dako, Carpinteria, CA,
USA) at 1:500 dilution was performed for 60 minutes.
Endogenous peroxidase was quenched with 0.1% natriu-
mazide/0.3% hydrogen peroxide in PBS. After post-anti-
body blocking, goat poly-horseradish peroxidase (HRP)
anti-mouse IgG (Immunologic, Duiven, The Nether-
lands) was added for 30 minutes. The colouring reaction
was developed with 3-amino-9-ethylcarbazole (AEC),
and counterstaining was performed with H & E.
Immunohistochemistry
Paraffin-embedded tissue samples of 5-μmt h i c k n e s s
were sequentially cut. Before blocking endogenous per-
oxidase activity with 1% hydrogen peroxide (Merck,
Amsterdam, The Netherlands) in 2% PBS, sections were
deparaffinised and rehydrated using xylene and a des-
cending alcohol series. Blocking was performed with the
following sequence: 2.5% periodic acid, 0.02% sodium
borohydride and Protein Block (Dako).
Detection of TGF-b3: After deparaffinisation, antigen
retrieval was performed in citrate buffer. Blocking was
done with Protein Block (Dako) for 20 minutes. TGF-b3
antibody (Abcam) was applied overnight in a humid
chamber at 4°C. Slides were rinsed in PBS, after which
biotinylated link antibody was added (LSAB2 System;
Dako) for 60 minutes. After slides were washed in PBS,
streptavidin conjugate (LSAB2 System) was applied for
60 minutes.
Detection of P-Smad2: Prior to the application of Pro-
tein Block for 20 minutes, sections were pretreated with
proteinase K (2 μg/mL in PBS) at 37°C for 30 minutes.
P-Smad2 (Ser465/467; Cell Signaling Technology) was
added overnight in a humid chamber at 4°C. Slides were
rinsed in PBS, after which biotinylated link antibody was
added (LSAB2 System) for 60 minutes. After PBS wash-
ing, streptavidin conjugate (LSAB2 System) was applied
for 60 minutes.
Detection of a-SMA: After quenching endogenous per-
oxidase activity with 0.3% H2O2 in methanol, slides were
heated in Tris-EDTA for 10 minutes at 100°C for antigen
retrieval. The a-SMA antibody (a-SMA/1, M851, 1A4
clone; Dako, Glostrup, Denmark) was applied for 60 min-
utes followed by post-antibody blocking (Immunologic)
for 15 minutes. After rinsing, goat poly-HRP against
mouse IgG (Immunologic) was added for 30 minutes fol-
lowed by PBS washing. All colouring reactions were
developed by using 3,3’-diaminobenzidine (Sigma Chemi-
cal Co.) followed by counterstaining with H & E. Unla-
belled samples were scored by an independent
pathologist. Scoring was rated as follows: no staining (-)
(except for staining in blood vessel walls), weak staining
(+), moderate staining (++) and intense staining (+++).
Detection of P-ERK1/2: Before blocking endogenous
peroxidase activity with 40% methanol and 1% H2O2
(Merck) in PBS, sections were deparaffinised and rehy-
drated using xylene and a descending alcohol series.
Antigen retrieval using proteinase K (2.5 μLi n1 0 0
mmol Tris, pH 9.0, and 50 mmol EDTA, pH 8.0) for 10
minutes at 37°C was followed by three washes with 0.1
mol Tris-buffered saline (pH 7.4) containing 0.02%
Tween 20 (TBST). Thereafter slides were incubated in
0.5% (Boehringer, Ingelheim, Germany) blocking reagent
(BMP) in TBST for 60 minutes at 37°C. Subsequently,
the P-ERK1/2 antibody (1:100; Cell Signaling Technol-
ogy) diluted in 0.5% BMP/TBST was applied overnight
at 4°C. Next, a species-specific biotinylated anti-IgG
antibody (1:600 dilution in 0.5% BMP/TBST) was
applied, followed by 45 minutes at 37°C. Incubation
with streptavidin-HRP (1:200 dilution in 0.5% BMP/
TBST) for 30 minutes at 37°C preceded and followed an
amplification step using biotinyl-tyramide. Staining was
carried out using AEC (Sigma Chemical Co., Zwijn-
drecht, The Netherlands) and Mayer’s haematoxylin
(Merck) according to the manufacturers’ instructions. A
water-based mounting solution was applied, and staining
was visualised by using an Olympus IX51 inverted
microscope equipped with the cell
F Soft Imaging System
(Olympus). Unlabelled samples were scored by an inde-
pendent researcher.
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Three-dimensional fibroblast-populated collagen lattice
(FPCL) contraction assays were carried out with primary
cell cultures from passages 4 through 6. The assay was
performed as described previously by others, with some
modifications [30-32]. The collagen lattices were pre-
pared by mixing a neutralising solution of COL1 (eight
parts 3 mg/mL COL1 (PurCol
®, Daiichi Sankyo, Parsip-
pany, New Jersey, USA) one part 10 × a-MEM (Invitro-
gen) and one part HEPES (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid) buffer, pH 9.0). Final col-
lagen and cell concentrations were adjusted to 2 mg/mL
and 86 × 103 cells/mL using PBS, respectively. The cell-
collagen mixture was aliquoted into PBS + 2% BSA-pre-
treated 24-well culture dishes (0.5 mL/well) and left to
polymerise for 1 hour at 37°C. In each well, to the top
of the polymerised lattice, we added 0.5 mL/well of
DMEM containing 10% FBS. After 2 days of incubation
at 37°C, the attached FPCLs were mechanically released
from the sides of the culture plates, and fresh media
supplemented with 0.5% FBS and the indicated sub-
stances were added. Images were obtained at various
time points over a 5-day period using the Odyssey Scan-
ner (LI-COR Biosciences). Collagen lattice areas were
measured using the corresponding Odyssey 2.1 software.
Statistical analysis
Values are expressed as means ± standard error of the
mean. For statistical comparisons of two samples, an
unpaired, a two-tailed Student’s t-test with distinction of
equal and unequal variances in a group (Levene’st e s t )
was used to determine the significance of differences
between means. In addition, a nonparametric Mann-
Whitney U test under the null hypothesis that the distri-
butions of both groups (control versus Dupuytren-
derived fibroblasts) were equal was performed for the
data set shown in Figure 2C. All of the relevant compar-
isons were considered to be significantly different at P <
0.05. Experiments were performed at least three times,
and representative results are shown.
Results
TGF-b/Smad signalling upregulated in DD
To evaluate the presence of TGF-b signalling in DD,
nodules from the palmar fascia of four DD patients were
surgically removed and compared to normal palmar fas-
cia from four control patients who had undergone carpal
tunnel release surgery (Table 1). Previous studies had
s h o w na ni n c r e a s ei nT G F - b1 levels in DD; we extended
these studies by examining TGF-b3, and also examined
P-Smad2 as a measure for active canonical TGF-b signal-
ling and a-SMA as a marker for myofibroblasts. Immu-
nohistochemical staining of the normal fascia revealed
weak TGF-b3a n dP - S m a d 2s i g n a l sa n dn oa-SMA
expression (except for pericytes in blood vessels). This
finding is in contrast to the tissues derived from DD
patients, which displayed strong staining for TGF-b3, P-
Smad2 and a-SMA. A high viable cell density, which is
indicative of the proliferative stage of the cords, was con-
firmed with H & E staining (Figure 1A and Table 2).
Tissue samples were further investigated for active TGF-
b signalling and for protein expression of key ECM com-
ponents induced during fibrogenesis (Figure 1B). On aver-
age, Smad2 and Smad3 protein expression levels were
significantly upregulated in DD patients compared to b-
actin protein expression levels. Furthermore, we detected
an increase in P-Smad2, but not P-Smad3, when normal-
ised to total Smad2 and Smad3, respectively, in DD
patients versus controls (Figure 1B and Additional file 1,
Supplementary Figure 1). In contrast, Smad1 protein
expression levels did not differ between control and DD
patient material. P-Smad1 was not detected in control or
DD samples (data not shown). Fibrogenesis ECM markers,
such as COL1 and fibronectin/ED-A, were detectable in
DD tissue but not in control samples. The myofibroblast
marker a-SMA was strongly upregulated in all four DD
patients (Figure 1B).
We next examined whether primary fibroblasts derived
from the tissue samples described above had similar
properties. We first investigated the presence of all three
TGF-b isoforms. In particular, the mRNA expression of
the TGF-b1 and TGF-b3 isoforms was significantly upre-
gulated in primary fibroblasts derived from DD tissue
samples, whereas TGF-b2 mRNA expression was barely
detectable (Figure 2A). Consistent with the results of the
immunohistochemistry performed on the tissue samples,
cultured Dupuytren’s fibroblasts stained positive for a-
SMA protein expression, whereas the control fibroblasts
contained only very little a-SMA protein expression. The
p e r c e n t a g e so fm y o f i b r o b l a s t si nD Dv e r s u sc o n t r o l
patients was 40% to 50% versus 2% to 5% (Figure 2B).
We then quantitatively compared the mRNA expres-
sion levels of components involved in TGF-b signalling
and fibrosis. On average, a nonparametric Mann-Whit-
ney U test (data not shown) followed by an unpaired
Student’s t-test revealed that Smad2 and Smad3 mRNA
Table 1 Overview of patients’ details
Patients Age, years Gender Tissue
Control 1 63 Female Palmar fascia
Control 2 32 Female Carpal ligament
Control 3 67 Male Palmar fascia
Control 4 38 Female Palmar fascia
Dupuytren 1 56 Female Palmar fascia
Dupuytren 2 43 Male Palmar fascia
Dupuytren 3 71 Male Palmar fascia
Dupuytren 4 47 Male Palmar fascia
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genes PAI-1 and CTGF, were significantly upregulated
in Dupuytren’s fibroblasts compared to control fibro-
blasts. mRNA expression of the ECM component COL1,
a2( COL1A2) gene and the cytoskeleton representative
a-SMA were also significantly increased, whereas the
expression of fibronectin mRNA did not differ from that
of control cells. The BMP signalling intracellular com-
ponent Smad1 was present at lower levels in Dupuytren
cells compared to normal fascia-derived cells
(Figure 2C). The fact that the null hypothesis of the
Mann-Whitney U test of equal distribution of control
(patients 1 through 4) and Dupuytren-derived (patients
1 through 4) fibroblasts was rejected in 87.5% of the
tested samples because we concluded that both control
and Dupuytren-derived fibroblasts have an independent
mRNA expression profile that also allows for statistical
comparison, which furthermore allows the statistical
analysis of pooled cell samples. Taken together, these
results suggest that TGF-b/Smad signalling is increased
in this fibroproliferative disease.
SB-431542 inhibited fibrogenic properties of Dupuytren’s
fibroblasts
Because TGF-b signalling was proposed to play an impor-
tant role in the etiopathogenesis of DD, we investigated
the expression of TGF-b isoforms and the involvement of
TGF-b-like signalling in the fibrogenic characteristics of
the disease. We observed that TGF-b1a n dT G F - b3
mRNA were expressed at much higher levels in Dupuyt-
ren’s than in control fibroblasts (Figure 3A), and we noted
a strong reduction in the elevated a-SMA expression in
Dupuytren’s fibroblasts upon treatment with SB-431542
(Figures 3B and 3C). Importantly, SB-431542 had strong
inhibitory effects in the collagen contraction assay on both
control and Dupuytren’s cells (Figure 3C and Additional
file 2, Supplementary Figure 2). Our data indicate that the
self-induced basal contraction of Dupuytren’sc e l l sw a s
caused by increased endogenous TGF-b-like Smad signal-
ling, which enhanced a-SMA expression and promoted
collagen contraction (Figure 3).
BMP6 attenuated TGF-b signalling in Dupuytren’s
fibroblasts
Because it has been suggested that BMPs, particularly
BMP7, can counteract TGF-b-induced fibrosis in the
Figure 1 Characterisation of Dupuytren’s disease and control tissue specimens. (A) Immunostaining of Dupuytren’sd i s e a s e( D D )a n d
control tissue specimens for transforming growth factor b3 (TGF-b3), phosphorylated Smad2 (P-Smad2), a-smooth muscle actin (a-SMA) and H
& E. Representative staining from DD patient 4 and control patient 1 is shown. Insets within each image are higher-magnification views.
Evaluation of all four control and DD tissue samples are described in Table 2. (B) Protein expression analysis for P-Smad2; phosphorylated Smad3
(P-Smad3); total Smad2, Smad3 and Smad1; a-SMA; type I collagen; and fibronectin/ED-A by Western blot analysis of 100 μg of total protein
extract isolated from four individual control patient-derived and four individual DD patient-derived tissue samples. b-actin was used as a loading
control.
Table 2 Evaluation of immunohistochemical staining
a
Patients TGF-b3 P-Smad2 a-SMA
Control 1 + ++ -
Control 2 ++ ++ -
Control 3 + ++ -
Control 4 + - -
Dupuytren 1 +++ ++ ++
Dupuytren 2 +++ +++ +++
Dupuytren 3 +++ +++ +++
Dupuytren 4 +++ ++ +++
aEvaluation of immunohistochemical staining was performed on four control
and four Dupuytren tissue samples. Positivity was graded on a scale from (-)
to (+++), with (-) representing no staining, (+) representing weak staining, (+
+) representing moderate staining and (+++) representing strong staining.
Staining in blood vessels was not included. The scoring was performed on
unlabelled samples by a pathologist not involved in the study. Representative
images are shown in Figure 1C.
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Page 6 of 15kidney, lung and liver, we investigated the effect of
BMPs on Dupuytren’s fibroblasts. BMP6, but not BMP7,
attenuated endogenous TGF-b-like signalling. Quantita-
tive PCR revealed that BMP6 strongly induced TGF-b1
mRNA expression in control cells but left the expression
of the TGF-b2a n dT G F - b3 isoforms unaffected (Figure
3A). In contrast to the control cells, in Dupuytren’s
fibroblasts BMP6 counteracted TGF-b1 and TGF-b3
mRNA expression (Figure 3A) and reduced SMAD2 and
SMAD3,b u tn o tSMAD1, mRNA expression (data not
shown).
As predicted on the basis of its antagonistic effects on
TGF-b-like signalling, BMP6 (but not BMP7) attenuated
a-SMA expression and counteracted the spontaneous
elevated contraction seen in Dupuytren’s fibroblasts
(Figures 3B to 3D and Additional file 2, Supplementary
Figure 2; data not shown). This inhibitory effect of
BMP6 was further potentiated by simultaneous
A B
C
Figure 2 Characterisation of primary Dupuytren’s fibroblasts and control fibroblasts. (A) Expression of TGF-b1, TGF-b2, and TGF-b3 mRNA
in Dupuytren’s fibroblasts and control fibroblasts is shown relative to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA expression.
Analysis was done by quantitative PCR. RNA input for Dupuytren’s fibroblasts and control cDNA synthesis consisted of an equal mixture of RNA
derived from all four Dupuytren’s fibroblasts (mixture 1 through 4) and all four control fibroblasts (mixture 1 through 4), respectively. Values are
expressed relative to the average of control (mixture 1 through 4) TGF-b1 mRNA values. (B) Immunostaining of Dupuytren’s and control
fibroblasts for a-SMA expression. Representative staining is shown for fibroblasts derived from Dupuytren’s patient 4 and control patient 1. (C)
Expression of plasminogen activator inhibitor 1 (PAI-1), Smad2, Smad3 and connective tissue growth factor (CTGF) mRNA in Dupuytren’s and
control fibroblasts derived from four individuals each is shown relative to GAPDH mRNA expression. Analysis was done by quantitative PCR.
Individual control (1 through 4) and Dupuytren’s (1 through 4) mRNA values are shown as well as their average values. Thus the average of
mRNA expression of the Dupuytren-derived fibroblasts is stated relative to the average of the control values.
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Page 7 of 15treatment with SB-431542 (Figures 3C and 3D and
Additional file 2, Supplementary Figure 2).
ERK1/2/MAP kinase signalling elevated in DD
It has been shown that TGF-b can activate non-Smad
signalling pathways, such as MAP kinase signalling
[9,10]. In addition, MAP kinases are activated by growth
factors such as PDGF that have been implicated in DD
[33,34]. We therefore investigated the phosphorylation
of p38, c-Jun N-terminal kinase (JNK) and ERK in con-
trol and Dupuytren’s tissue samples as well as in pri-
mary cells. While we did not detect phosphorylation of
p38 and JNK (data not shown), phosphorylation of
ERK1/2 was significantly increased in Dupuytren’s tissue
samples compared to control samples (Figures 4A and
4B). Similar results were obtained with fibroblasts iso-
lated from Dupuytren’s and control patients (Figures 4C
and 5A).
We next determined the direct effects of TGF-b on the
phosphorylation of ERK1/2 in Dupuytren’s fibroblasts.
We found that 5 minutes of TGF-b3 treatment induced a
further increase in the phosphorylation of ERK1/2, which
was inhibited by SB-431542 to a level lower than the
basal level (Figure 4C). The presence of BMP6, however,
had only marginal effects on the direct TGF-b3-induced
phosphorylation of ERK1/2 (Figure 4C). In addition to its
A
B C
D
Figure 3 Effects of SB-431542 and bone morphogenetic protein 6 on Dupuytren’s and control fibroblasts. (A) Quantitative PCR was used
to determine the average expression of TGF-b1, TGF-b2 and TGF-b3 mRNA from control (mixture 1 through 4) and Dupuytren’s (mixture 1
through 4) fibroblasts relative to GAPDH mRNA expression in the presence or absence of 100 ng/mL bone morphogenetic protein 6 (BMP6) for
18 hours. All values are expressed relative to the average of the control (1 through 4) TGF-b1 mRNA values. (B) Immunofluorescence of a-SMA in
control and Dupuytren’s fibroblasts treated for 72 hours with 20 μmol SB-431542 (+) in combination with or without 100 ng/mL rec. BMP6.
Dimethyl sulfoxide (DMSO)-treated cells (-) were used as an internal control. Alexa Fluor 488 (green), a-SMA; 4’,6-diamidino-2-phenylindole (blue),
DNA. Representative staining is shown for Dupuytren’s patient 4 and control patient 1. (C) Quantification of a-SMA-expressing control (mixture 1
through 4) and Dupuytren (mixture 1 through 4) cells after treatment with SB-431542 (20 μmol) in the presence or absence of rec. BMP6 (100
ng/mL) for 72 hours as depicted in Figure 3B. (D) Fibroblast-populated collagen lattice (FPCL) of control (1 through 4) and Dupuytren’s( 1
through 4) fibroblasts treated with DMSO (-) or 20 μmol SB-431542 (+) in the presence or absence of 100 ng/mL rec. BMP6. Quantification of the
average contractions of control (1 through 4) and Dupuytren’s (1 through 4) fibroblasts was calculated after 72 hours of treatment.
Representative images are shown in Additional file 2, Supplementary Figure 2.
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Page 8 of 15direct effect, TGF-b3 also induced an increase in ERK1/2
phosphorylation after 18 hours of stimulation. Interest-
ingly, while SB-431542 showed only marginal effects on
this sustained activation, BMP6 strongly attenuated this
effect after 18 hours (Figure 4C).
The sustained effect of TGF-b3o nE R K 1 / 2w a sl i k e l y
indirect and may have occurred via the TGF-b-mediated
induction of growth factors. Indeed, PDGF-B and
PDGF-A mRNA expression in particular were signifi-
cantly upregulated in Dupuytren’s fibroblasts and were
strongly induced by TGF-b3 treatment (Figure 4D and
data not shown). SB-431542 compound or BMP6 coun-
teracted the TGF-b-induced increase in PDGF-B mRNA
expression (Figure 4D).
Targeting of TGF-b type I receptor and ERK1/2/MAP
kinase pathways in Dupuytren’s fibroblasts
We next set out to determine whether the elevated
TGF-b/Smad and MAP kinase signalling pathways were
causally linked to an increase in the expression of key
fibrotic and proliferation proteins by interfering with
these pathways using the ALK4, ALK5 and ALK7
AB
CD
Figure 4 Elevated phosphorylated extracellular signal-regulated kinase 1/2 expression in Dupuytren’st i s s u es a m p l e s . (A)
Immunostaining for phosphorylated extracellular signal-regulated kinase 1/2 (P-ERK1/2) and secondary antibody control (P-ERK1/2 antibody
omitted) of Dupuytren’s and control tissue specimens. Representative staining from Dupuytren’s patient 4 and control patient 1 is shown. (B)
Quantitative analysis of P-ERK1/2-positive cells (shown in Figure 4A) from three control and three Dupuytren’s tissue samples expressed as
percentages. (C) Western blot analysis of lysates from pooled Dupuytren’s fibroblasts (mixture 1 through 4) to determine P-ERK1/2 in untreated
or rec. TGF-b3 (0.1 ng/mL)-treated cells for either 5 minutes or 18 hours in the presence or absence of SB-431542 (20 μmol) or rec. BMP6 (100
ng/mL). (D) Expression of PDGF-B (platelet-derived growth factor B) mRNA from four controls (mixture 1 through 4) and Dupuytren’s fibroblasts
(mixture 1 through 4) stimulated with 0.1 ng/mL rec. TGF-b3 in the presence or absence of 20 μmol SB-431542 or 100 ng/mL rec. BMP6 for 18
hours. Quantitative PCR was performed, and values are expressed relative to the average of the control (mixture 1 through 4) mRNA values
using GAPDH as an internal reference.
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Page 9 of 15inhibitor SB-431542 [8,30], the MEK1 inhibitor
PD98059 [35] and BMP6. Treatment of Dupuytren’s
fibroblasts with SB-431542 completely inhibited elevated
basal P-Smad2 levels and also attenuated P-ERK1/2
levels. This suggests that these increased basal activities
are due to TGF-b or TGF-b-like ligands that are
secreted by Dupuytren’s fibroblasts themselves. PD98059
also strongly inhibited elevated basal P-ERK1/2 levels
and had no significant effect on P-Smad2 levels (Figure
5A). Both treatments were associated with decreased
expression of fibrotic marker proteins such as COL1
and a-SMA and reduced expression of the proliferation
marker c-myc proto-oncogene (Figure 5A). Both SB-
431542 and PD98059 treatment also inhibited COL1A2,
CTGF and PAI-1 gene expression (Additional file 3,
Supplementary Figure 3). The inhibitory effects of SB-
A
B
C
D
Figure 5 TGF-b-induced ERK/mitogen-activated protein kinase signalling in Dupuytren’s disease is inhibited by selective low-
molecular-weight kinase inhibitors and BMP6. (A) Western blot analysis for phosphorylated Smad2 (P-Smad2), P-Smad1, P-ERK1/2, type I
collagen, a-SMA, c-myc and total ERK1/2 using specific antibodies on pooled control (mixture 1 through 4) and Dupuytren’s (mixture 1 through
4) fibroblasts treated with SB-431542 (20 μmol), mitogen-activated protein kinase kinase 1 (MEK1) inhibitor PD98059 (10 μmol) and rec. BMP6
(100 ng/mL) for 18 hours. (B) Western blot analysis for P-ERK1/2, a-SMA, c-myc and total ERK1/2 using specific antibodies on pooled Dupuytren’s
fibroblasts (mixture 1 through 4) treated with SB-431542 (20 μmol), MEK1 inhibitor PD98059 (10 μmol), PDGF receptor (STI571, also called
imatinib mesylate), epidermal growth factor receptor (PKI166) and vascular endothelial growth factor receptor (PTK787/ZK 222584) kinase
inhibitors (10 μmol) for 18 hours. (C) 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS)-based
proliferation assay with pooled Dupuytren’s fibroblasts (mixture 1 through 4) treated for 4 days with SB-431542 (20 μmol) and/or the MEK1
inhibitor PD98059 (10 μmol). Absorbance at 490 nm was measured daily, and the proliferation rate is stated relative to untreated Dupuytren’s
fibroblasts (mixture 1 through 4) at day 0. (D) FPCL on pooled control (mixture 1 through 4) and Dupuytren’s (mixture 1 through 4) fibroblasts
treated with SB-431542 (20 μmol) and/or PD98059 (10 μmol) for 72 hours.
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Page 10 of 15431542 or PD98059 were potentiated by cotreatment
with BMP6 (Figure 5A). Cotreatment with SB-431542/
BMP6 and PD98059/BMP6 combinations decreased the
levels of P-ERK1/2, COL1 and a-SMA to undetectable
levels in Dupuytren’s cells, which also was seen in
untreated control cells. The c-myc level was significantly
downregulated by PD98059/BMP6 and reached the low
levels observed in control cells (Figure 5A).
We found that TGF-b3 strongly induced PDGF (Fig-
ure 4D), which, via its receptor, can activate ERK1/2/
MAP kinase signalling. To determine the role of PDGF
signalling in the augmented ERK1/2 phosphorylation
observed in DD, we treated Dupuytren’s fibroblasts with
a selective PDGF receptor tyrosine kinase inhibitor
(STI571, also known as imatinib mesylate) [36] and
compared its effect with the effects of the inhibitors SB-
431542 and PD98059. EGF receptor and VEGF receptor
tyrosine kinase inhibitors [37,38] were used as specificity
controls for the PDGF receptor kinase inhibitor. The
PDGF receptor kinase inhibitor led to strong but incom-
plete decreases in ERK1/2 phosphorylation and c-myc
expression (Figure 5B). Its effect was weaker than
cotreatment of Dupuytren’s fibroblasts with SB-431542
and PD98059. The EGF and VEGF receptor kinase inhi-
bitors showed only minor effects. We could find no sig-
nificant inhibition of the elevated a-SMA expression
upon challenge of Dupuytren’s fibroblasts with STI561
(Figure 5B), however, which is consistent with previous
findings that link PDGF to proliferation and not to a
myofibroblast transdifferentiation response [39].
The inhibitory effects of PD98059 suggest that the
ERK1/2 MAP kinase pathway plays an important role in
the increased fibrotic characteristics of Dupuytren’s
fibroblasts compared to control fibroblasts. When we
stimulated Dupuytren’s fibroblasts with TPA, which
activates ERK1/2/MAP kinase pathways (as well as other
pathways), we found elevated a-SMA expression and
collagen contraction (Additional file 4, Supplementary
Figure 4). Thus, ERK/MAP kinase signalling may be suf-
ficient to weakly mediate the fibroproliferative properties
observed in Dupuytren’s fibroblasts.
Taken together, our results indicate that both the
TGF-b/Smad and ERK1/2 MAP kinase signalling path-
ways contribute to the fibrogenic responses of Dupuyt-
ren’s fibroblasts. We therefore determined whether we
could normalise the fibroproliferative characteristics of
Dupuytren’s fibroblasts by targeting TGF-b-like signal-
ling and ERK1/2/MAP kinase with SB-431542 and the
MEK1 inhibitor PD98059, respectively. Concurrent
treatment of Dupuytren’s fibroblasts with SB-431542
and PD98059 abrogated ERK1/2 phosphorylation as well
as a-SMA and c-myc expression (Figure 5B). Consistent
with this observation, we found that treatment with SB-
431542 and/or PD98059 strongly inhibited the elevated
basal proliferation of Dupuytren’s fibroblasts and had
only minor effects on the proliferation rate of normal
fibroblasts (Figure 5C and Additional file 5, Supplemen-
tary Figure 5). The high spontaneous contraction rate in
Dupuytren’s fibroblasts was completely blocked by
cotreatment with SB431542 and PD98059 (Figure 5D).
Discussion
DD is a chronic, fibroproliferative disorder that is most
likely induced by overactive cytokines such as TGF-b,
which is thought to play a prominent role by stimulating
Dupuytren’s fibroblasts to produce excessive levels of
ECM proteins and by promoting their contractile phe-
notype [1]. In line with the results of previous studies,
we found that biopsies and fibroblasts derived from pri-
mary cultures from affected areas in patients with DD
had elevated expression levels of TGF-b, in particular
the TGF-b1a n dT G F - b3 isoforms, and that this corre-
lated with increases in the expression levels of SMA,
CTGF, fibronectin and collagen in Dupuytren’sf i b r o -
blasts compared to controls [18,21].
TGF-b can signal via the Smad signalling pathways.
We observed that patients with DD showed elevated
expression of Smad2 and Smad3, but not Smad1. Of
note, whereas P-Smad2 levels were found to be elevated,
this was not clear for P-Smad3 levels. Smad2 and
Smad3 may have distinct roles. In a recent article, inves-
tigators demonstrated that Smad3 is a negative regulator
of a-SMA expression and the activation of the myogenic
program in the epithelium [40]. When we challenged
Dupuytren’s fibroblasts with SB-431542, which inhibits
TGF-b-like signalling pathways, the expression of key
fibrotic markers such as PAI-1, CTGF, a-SMA and
COL1 was decreased. Previous characterisation of the
promoters of these target genes showed that they are
regulated in a Smad-dependent manner [41,42]. More-
over, application of SB-431542 revealed that the high
amount of spontaneous contraction of Dupuytren’s
fibroblasts, when embedded in a collagen lattice, was
caused by overactive TGF-b-like signalling. TGF-b
receptor kinase inhibitors have been shown to inhibit
fibrotic responses in other cells in vitro and in vivo [29].
In recent years, a strong link has been established
between TGF-b-induced fibrosis and BMP expression
and signalling. Challenging the fibrogenic properties of
Dupuytren’s fibroblasts with BMP6 inhibited the gene
expression of TGF-b1a n dT G F - b3 and their respective
downstream Smad2 and Smad3 effectors. Whereas pre-
vious studies attributed antifibrotic effects to BMP7, a
close homolog of BMP6 [28], we were unable to demon-
strate this for Dupuytren’s fibroblasts. One could specu-
late whether BMP6 could compete with TGF-b for the
recruitment of distinct receptors, thereby limiting TGF-
b activity. Our data suggest a novel level of cross-talk,
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Page 11 of 15as previous studies have suggested that BMPs had an
inhibitory effect on the TGF-b/Smad pathway through
the formation of mixed Smad1/5-Smad2/3 complexes
[43,44]. It is interesting that BMP6 in particular had an
antagonising effect on TGF-b-driven DD, because it has
been shown that myofibroblast progenitor cells derived
from patients with diabetes are deficient in BMP6
expression [45], and there is some evidence of a rela-
tionship between diabetes and DD [46]. In another
study, BMP6 and BMP7 were found to have differential
effects on chemotaxis via a Smad4-independent, phos-
phoinositide 3-kinase-dependent pathway [47]. It would
be worthwhile to explore whether similar mechanisms
are of relevance in Dupuytren’s fibroblasts. Although
BMP6 may inhibit fibrotic responses, in discussing it as
a potential therapeutic agent, one needs to take into
account BMP6’sa c t i o no nn o r m a lf i b r o b l a s t sa n di t s
strong osteoinductive properties [48].
Figure 6 Schematic representation of perturbed TGF-b/Smad and mitogen-activated protein kinase signalling pathways in
Dupuytren’s fibroblasts. The TGF-b/Smad canonical Smad2/3 pathway and the noncanonical ERK1/2 mitogen-activated protein (MAP) kinase
signalling pathways are depicted, as well as the PDGF-induced Ras/Raf/MEK/ERK1/2/MAP kinase pathway. TGF-b induces the production of PDGF
and other growth factors. The symbols of corresponding downstream regulated genes are shown in italics. Inhibition by STI571, SB-431542 and
PD98059 of the aberrantly overactivated signalling pathways in Dupuytren’s fibroblasts is indicated. The mechanism by which BMP6 inhibits TGF-
b expression and downstream responses is unclear. SB-431542 inhibits not only TGF-b/activin receptor-like kinase 5 (ALK5) signalling but also
activin/ALK4 and nodal/ALK7 signalling. Our experiments do not rule out a role for these signalling pathways in Dupuytren’s fibroblasts. Our data
suggest that the TGF-b/Smad and PDGF/ERK MAP kinase pathways are targets for therapeutic intervention strategies to treat DD.
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active ERK1/2 signalling, but neither the JNK nor the
p38 MAP kinase signalling pathway showed increased
activity. This could be due to both direct TGF-b-
induced ERK1/2 phosphorylation, since it was observed
within 5 minutes and inhibited by SB431542, and indir-
ectly through the induction of PDGF expression, which
can stimulate ERK1/2 phosphorylation (schematically
represented in Figure 6). Consistent with the latter idea,
we found that treatment with the PDGF receptor inhibi-
tor STI571 strongly mitigated the expression of phos-
phorylated ERK1/2.
The elevated ERK1/2 MAP kinase pathway could be
linked to the elevated fibroproliferative characteristics of
Dupuytren’s fibroblasts. Treatment of cells with
PD98059 inhibited the expression of fibrotic and prolif-
eration markers. A role for MAP kinase signalling, also
in cooperation with the Smad pathway, has been
described for many TGF-b target genes [49-52]. In line
with its potent inhibitory effects on fibroproliferative
markers, spontaneous collagen contraction and elevated
proliferation were inhibited by PD98059. Moreover, the
finding that TPA induced ERK1/2 phosphorylation and
collagen contraction suggests that activation of this
pathway may be sufficient to induce contraction. BMP6
was not able to counteract this TPA-induced ERK
response, which is in line with its proposed inhibitory
actions further upstream at the level of TGF-b and
Smad expression. Consistent with our results, inhibition
of ERK1/2 MAP kinase signalling has been shown to
mitigate fibrotic responses in scleroderma [53,54]. Our
observations suggest a role for elevated PDGF signalling
in promoting the proliferation of Dupuytren’sf i b r o -
blasts. Of note, overactive PDGF signalling has been
implicated in fibrosis in multiple tissues [55-57], and
treatment with PDGF receptor kinase inhibitors has
been shown to inhibit fibrosis [58,59].
Importantly, when both TGF-b receptors and ERK1/2
pathways were inhibited in Dupuytren’sf i b r o b l a s t s
through simultaneous application of SB-431542 and
PD98059, a complete block of the elevated basal prolif-
eration and contraction was observed, which in turn
commuted the Dupuytren’s fibroblast phenotype into
‘normal’ fibroblasts.
Conclusions
Both the TGF-b and ERK1/2 MAP kinase pathways
cooperated in mediating the enhanced proliferation and
high spontaneous contraction of Dupuytren’s fibroblasts.
Taken together, our data indicate that the TGF-b/Smad
and ERK1/2 MAP kinase pathways are prime targets for
the development of nonsurgical intervention strategies
to treat patients with DD. For example, concurrent topi-
cal application of inhibitors such as SB-431542 and
PD98059 into the DD area could block fibroproliferative
responses and recurrence in DD while preventing the
potential problems associated with systemic administra-
tion of such compounds (schematically represented in
Figure 6).
Additional material
Additional file 1: Quantification of total Smad and phosphorylated
Smad (P-Smad) protein expression levels as depicted in Figure 1B.
Quantification was performed by densitometric analysis using the
Odyssey system (LI-COR Biosciences). All values are expressed relative to
b-actin protein expression levels (C, Control; D, Dupuytren).
Additional file 2: Fibroblast-populated collagen lattice (FPCL) of
controls’ (1 through 4) and Dupuytren’s patients’ (1 through 4)
fibroblasts treated with dimethyl sulfoxide (DMSO) (-) or 20 μmol
SB-431542 (+) in the presence or absence of 100 ng/mL rec. bone
morphogenetic protein 6 (BMP6). Corresponding images demonstrating
the quantification of contraction in Figure 3D are shown.
Additional file 3: Quantitative PCR was used to determine the
average expression of a-SMA, Smad1, Smad2, Smad3, PAI-1
(plasminogen activator inhibitor 1), fibronectin, CTGF, c-myc and
COL1A2 mRNA from control (mixture 1 through 4) and Dupuytren’s
(mixture 1 through 4) fibroblasts relative to GAPDH mRNA
expression in the presence or absence of SB-431542 (20 μmol) and/
or the MEK1 inhibitor PD98059 (10 μmol) and/or 100 ng/mL BMP6
for 18 hours. All values are expressed relative to the average of the
untreated control (1 through 4) mRNA values.
Additional file 4: Top: FPCL on control (mixture 1 through 4) and
Dupuytren’s fibroblasts (mixture 1 through 4) treated with 12-O-
tetradecanoylphorbol-13-acetate (TPA) (100 nmol) in the presence
or absence of rec. BMP6 (100 ng/mL) for 72 hours. Middle:
Representative images of each condition are shown. Bottom: Western
blot analysis of phosphorylated extracellular signal-regulated kinase 1/2
(P-ERK1/2) and a-smooth muscle actin (a-SMA) on primary control
(mixture 1 through 4) and Dupuytren’s fibroblasts (mixture 1 through 4)
treated with TPA (100 nmol) in the absence or presence of rec. BMP6
(100 ng/mL) for 18 hours are depicted in the lower panel. b-actin was
included as a loading control.
Additional file 5: 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS)-
based proliferation assay of pooled control fibroblasts treated for
four days with SB-431542 (20 μmol) and/or the mitogen-activated
protein kinase kinase 1 (MEK1) inhibitor PD98059 (10 μmol) where
indicated. Absorbance at 490 nm was measured daily, and the
proliferation rate is stated relative to untreated cells at day 0.
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